Affymetrix and Empire Genomics sign licensing agreement

| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
SANTA CLARA, Calif.—AffymetrixInc. announced recently that Empire Genomics LLC has obtained a non-exclusive,worldwide license to a number of Affymetrix patents covering the manufacturing,use and sales of nucleic acid microarrays and related products and services forcomparative genomic hybridization (CGH). The arrays and services may be usedfor research or diagnostic purposes. Financial details of the license were notdisclosed.

"This agreement with Affymetrix enables Empire Genomics tobring its innovative genomics platform to market while continuing theadvancement of personalized medicine," says Anthony Johnson, president and CEOof Empire Genomics. "We fully expect that focusing in the field of copy numbervariation will lead to the discovery of the genomic causes of multiplediseases, as well as advanced therapeutic treatment strategies."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue